Advances in the treatment of coronary artery disease remained steady in 2025, as in recent years, but the past 12 months also ...

CLOSURE-AF and CREST-2 were widely read, but stories on GLP-1s, DOACs in AF, and a new PCSK9 inhibitor were popular, too.

The drug is the second cardiac myosin inhibitor to get regulatory signoff in the United States, following mavacamten in 2022.

Government entities threw CV specialists for a loop in 2025 with changes that will inevitably affect patient care.

New evidence for treatment of pulmonary embolism, asymptomatic carotid stenosis, and CLTI led the way in 2025.

VESALIUS-CV was big in 2025, but studies looking at triglycerides, CRISPR, and oral GLP-1s also made the highlight reel.

Other hot topics included new data on LAAO and conduction-system pacing, plus the go-ahead for ablation in ASCs.

Health-related social needs in HF, removing age from frailty scores, CIED concerns about smartwatches, and more.

As research continues into how AI will impact practice, there are open questions about medical training, regulation, and more ...

In 2025, cardiology delved deeper into sex-specific risk factors and how to leverage them in prevention, Stacey Rosen says.

By improving BP control and treatment adherence, use of fixed-dose combination therapies is expected to drive down CV events ...

Gaxiola López shaped the field of interventional cardiology, with colleagues saying he’ll be remembered as a “visionary.” ...